Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/56301
DIAGNOSTIC BIOMARKERS FOR ACTIVE TUBERCULOSIS: PROGRESS AND CHALLENGES
Author
Affilliation
Universidade Federal da Bahia. Programa de Pós-graduação em Ciências da Saúde. Salvador, BA, Brasil / Instituto Couto Maia. Salvador, BA, Brasil / Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative. Salvador, BA, Brasil.
Division of Infectious Diseases. Department of Medicine. Johns Hopkins University School of Medicine. Baltimore, MD, USA.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative. Salvador, BA, Brasil / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil / Universidade Federal do Rio de Janeiro. Programa de Pós-graduação em Clínica Médica. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative. Salvador, BA, Brasil /Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.
Instituto Couto Maia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Center of Data and Knowledge Integration for Health. Salvador, BA, Brasil.
Department of Medicine. Centre for Emerging Pathogens. Rutgers-New Jersey Medical School. Newark, NJ, USA.
Department of Medicine. Centre for Emerging Pathogens. Rutgers-New Jersey Medical School. Newark, NJ, USA.
South African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine. Division of Immunology. Department of Pathology. University of Cape Town. Cape Town, South Africa.
Division of Infectious Diseases. Department of Medicine. Vanderbilt University Medical Center. Nashville, TN, USA.
Division of Infectious Diseases. Department of Medicine. Johns Hopkins University School of Medicine. Baltimore, MD, USA.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative. Salvador, BA, Brasil / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil / Faculdade de Tecnologia e Ciências. Curso de Medicina. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Curso de Medicina. Salvador, Brasil.
Division of Infectious Diseases. Department of Medicine. Johns Hopkins University School of Medicine. Baltimore, MD, USA.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative. Salvador, BA, Brasil / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil / Universidade Federal do Rio de Janeiro. Programa de Pós-graduação em Clínica Médica. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative. Salvador, BA, Brasil /Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.
Instituto Couto Maia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Center of Data and Knowledge Integration for Health. Salvador, BA, Brasil.
Department of Medicine. Centre for Emerging Pathogens. Rutgers-New Jersey Medical School. Newark, NJ, USA.
Department of Medicine. Centre for Emerging Pathogens. Rutgers-New Jersey Medical School. Newark, NJ, USA.
South African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine. Division of Immunology. Department of Pathology. University of Cape Town. Cape Town, South Africa.
Division of Infectious Diseases. Department of Medicine. Vanderbilt University Medical Center. Nashville, TN, USA.
Division of Infectious Diseases. Department of Medicine. Johns Hopkins University School of Medicine. Baltimore, MD, USA.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative. Salvador, BA, Brasil / Universidade Salvador. Curso de Medicina. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil / Faculdade de Tecnologia e Ciências. Curso de Medicina. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Curso de Medicina. Salvador, Brasil.
Abstract
Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker- or biosignature-based diagnostics using point-of-care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen- and host-based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake.
Share